Kendall Capital Management Has $2.40 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Kendall Capital Management boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.9% in the fourth quarter, HoldingsChannel reports. The fund owned 6,795 shares of the biotechnology company’s stock after buying an additional 253 shares during the quarter. Kendall Capital Management’s holdings in United Therapeutics were worth $2,398,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC boosted its position in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock valued at $210,869,000 after buying an additional 30,931 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after buying an additional 50,409 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of United Therapeutics by 2.2% during the 4th quarter. Assetmark Inc. now owns 429,160 shares of the biotechnology company’s stock valued at $151,425,000 after buying an additional 9,203 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 116,464 shares of company stock valued at $42,396,244 in the last three months. Company insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on UTHR shares. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Up 2.7 %

Shares of NASDAQ UTHR opened at $315.91 on Friday. The business’s 50 day moving average is $354.52 and its two-hundred day moving average is $359.94. The company has a market cap of $14.19 billion, a P/E ratio of 13.87, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business posted $4.36 EPS. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.